Artios Pharma Limited announced a three-year research collaboration with Novartis to discover and validate next generation DNA Damage Response targets to enhance Novartis' Radioligand Therapies. The companies will perform target discovery and validation, and Novartis will select up to three exclusive DNA Damage Response targets, and receive worldwide rights on these targets to be utilized with its Radioligand Therapies.
Novartis will make an up-front payment of $20 million and provide near term research funding to support the collaboration. Artios noted that it will be eligible to receive up to $1.3 billion in discovery, development, regulatory and sales-based milestones in addition to royalty payments.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.